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Introduction {#sec005}
============

Radiation therapy is the most effective adjuvant treatment in breast cancer after surgery \[[@pone.0131736.ref001]--[@pone.0131736.ref003]\]. Lungs, located beneath the breasts, are among the most critical organs in radiation therapy in the treatment planning for breast cancer. As the essential organ for respiration, reduction of lung damage during breast cancer radiotherapy is important. Radiation pneumonitis (RP), which decreases quality of life (QoL), is the most common pulmonary complication in patients receiving breast irradiation. If it occurs, acute RP usually develops 4--12 weeks after completion of radiotherapy and presents symptoms as a dry cough, dyspnea and low-grade fever \[[@pone.0131736.ref004], [@pone.0131736.ref005]\]. If the incidence of symptomatic RP (SRP) is reduced, not only the QoL but also the compliance of breast cancer patients may be improved.

Several researchers have investigated the role of dosimetric predictive factors for RP in three-dimensional radiation therapy treatment planning, such as the percentage of the total lung volume exceeding a defined dose (Vdose) and ipsilateral mean lung dose (MLD), to reduce RP and/or escalate the radiation dose. Hernando *et al*. \[[@pone.0131736.ref006]\], Ramella *et al*. \[[@pone.0131736.ref007]\] and Graham *et al*. \[[@pone.0131736.ref008]\] have associated the percentage of lung volume receiving more than 20 Gy (V20), percentage of lung volume receiving more than 30 Gy (V30) and MLD with the risk of developing RP \[[@pone.0131736.ref007]\]. With the progression of radiation therapy techniques, intensity-modulated radiation therapy (IMRT) and hybrid IMRT used concurrently with conventional and IMRT beams create the most conformal dose distribution. However, more normal tissue receiving a low dose has been considered \[[@pone.0131736.ref009]--[@pone.0131736.ref011]\]. Additionally, the incidence of RP may depend on patient-related variables \[[@pone.0131736.ref012]\]. The risk factors for RP particularly with symptoms after radiation therapy using these novel technologies in breast cancer patients should be reviewed and analyzed more extensively.

Conventionally, the normal tissue complication probability (NTCP) model can be fitted using either univariate or multivariate logistic regression analysis to predict the incidence of SRP. However, the development of SRP likely depends on a variety of risk factors. Several variables such as clinical and patient-related factors, which may have important effects on the risk of radiation-induced complications, need to be considered. Therefore, evaluating the dose distribution of the lung volume involved as well as other potential clinical and treatment-related risk factors is important to develop predictive models.

The optimal number of risk factors for the model developed is controversial when the multivariate logistic regression model is used. Recently, Xu *et al*. \[[@pone.0131736.ref013], [@pone.0131736.ref014]\] and Lee *et al*. \[[@pone.0131736.ref015]--[@pone.0131736.ref017]\] recommended the least absolute shrinkage and selection operator (LASSO) method for multivariate logistic regression NTCP modeling. The LASSO method is based on shrinkage estimates and is widely used in the field of statistics. The advantages of LASSO include a smaller mean squared error (MSE), handling of the multicollinearity problem, overall variable selection and coefficient shrinkage \[[@pone.0131736.ref017], [@pone.0131736.ref018]\] and ease of implementation \[[@pone.0131736.ref019]--[@pone.0131736.ref023]\]. Therefore, in this study we developed a multivariate logistic NTCP regression model with LASSO to make valid predictions regarding the incidence of RP particularly with symptoms among breast cancer patients treated with hybrid IMRT.

Methods {#sec006}
=======

Study population {#sec007}
----------------

Breast cancer patients referred to our department for adjuvant radiation therapy between April 2012 and November 2014 were evaluated, and those treated with hybrid IMRT were enrolled in this study. The patients' characteristics, including basic information, disease status, and radiation therapy dosimetric parameters, were reviewed. This study was approved by Chang Gung Memorial Hospital institutional review boards of the hospital (103-0217B), and all participants provided written informed consent for the inclusion of their data in this retrospective analysis. All experiments were performed in accordance with relevant guidelines and regulations.

Treatment techniques {#sec008}
--------------------

The treatment plans were designed using the Philips Pinnacle^3^ treatment planning system (version 9.2, Philips, Fitchburg, WI, USA). Treatment was delivered by the computer-controlled auto-sequencing segment or the dynamic multileaf collimator of a linear accelerator \[Varian Clinac 21 EX (Varian Medical Systems, Palo Alto, CA, USA) or Elekta Precise (Elekta, Crawley, UK)\]. For each patient, treatment plans were implemented using the hybrid IMRT technique. The dose prescribed for the PTV was 50.4 Gy in 28 fractions. The optimization constraint ensured that the 95% isodose line encompassed 95% of the PTV (V95% ≥ 47.88 Gy).

The hybrid IMRT technique was combined with conventional and IMRT beams. The conventional conformal beams with medial and lateral beams designed for the tangential fields were used without wedges, and two anterior oblique IMRT beams were added \[[@pone.0131736.ref009]--[@pone.0131736.ref011]\]. The tangential beams were chosen so as to minimize exposure to the heart and lungs while ensuring adequate coverage of the PTV. The fields were extended 2--3 cm anteriorly of the breast to provide skin flashing of the region. The relative weights of the conventional beams were typically ≤ 83% of the dose delivered from conventional beams. The plans were optimized to cover the PTV and spare surrounding normal tissue (such as the lungs, heart and contralateral breast) as much as possible. All data were based on the dose-volume-histograms (DVHs) obtained using Pinnacle^3^ with a bin size resolution of 0.01 Gy. The resolution of the dose calculation was 2.5 mm for all IMRT plans.

Evaluation of RP {#sec009}
----------------

The RP symptoms were evaluated during and after radiation therapy. Clinically symptomatic was defined according to the modified Common Toxicity Criteria of the National Cancer Institute of Canada (CTC-NCIC) \[[@pone.0131736.ref005], [@pone.0131736.ref024]\]: grade 0, no pneumonitis (no registered respiratory symptoms or respiratory problems independent of RT as determined by the oncologist); grade 1, mild pneumonitis (respiratory symptoms, i.e., cough and/or dyspnea with or without fever determined by the oncologist to be radiation-therapy-induced but not requiring steroids); grade 2, moderate complications (same as grade 1, but with impaired daily function and steroid treatment requirement). The most serious grading of the patient during and after radiation therapy was specified as the symptomatic severity.

Chest computed tomography (CT) was evaluated 1--3 months after completion of radiation therapy. Density changes on chest CT were evaluated by comparing with the CT image prior to radiation therapy for radiation therapy treatment planning. On both occasions, slices from three lung levels were examined (the central CT slice, the slice just above the heart contour and an apical slice at the clavicle level). An increase in density was graded according to a CT-adapted modification of Arriagada's classification (0 = no change; 1 = low opacity in linear streaks; 2 = moderate opacity; 3 = complete opacity). The method used was introduced by Arriagada *et al*. and Lind *et al*., and the details can be found in the references\[[@pone.0131736.ref025], [@pone.0131736.ref026]\].

The final endpoint, acute SRP, was defined as patients with symptomatic pneumonitis combined with density changes ≥ grade 1 as measured on CT images.

Statistical analysis {#sec010}
--------------------

Data were fitted to a multivariate logistic NTCP regression model, and the method has been described in previous studies \[[@pone.0131736.ref015], [@pone.0131736.ref016], [@pone.0131736.ref027], [@pone.0131736.ref028]\]. For each patient, predictive values were calculated for each set of risk factors based on the multivariate logistic regression coefficients according to the following formula: $$NTCP = {(1 + e^{- S})}^{- 1},\ \text{where}\ S = \beta_{0} + {\sum\limits_{i = 1}^{n}{\beta_{i} \cdot x_{i}}}$$ where *n* is the number of risk factors in the built model, variable *x* ~*i*~ represents the different risk factors and *β* ~*i*~ is the corresponding regression coefficient.

For each patient, 31 candidate risk factors were included initially in the variable selection procedure of this study. The candidate factors included 12 clinical and 19 dosimetric factors. The clinical candidate factors were age, BMI, Lung (d), Total (d), tumor site, chemotherapy, radiation energy, irradiation of IMNs, irradiation of supraclavicular fossa (SCF), surgery method, T stage, and N stage. The dosimetric candidate factors were the mean dose administered to the ipsilateral lung (MLD), the percentage of the ipsilateral lung volume (%) that received doses of 5--50 Gy at selected steps (IV5 \~IV50) and the absolute ipsilateral lung volume (cc) that received doses of 5--50 Gy at selected steps (AIV5 \~AIV50). We used the LASSO method to select the optimal number of potential risk factors for the predictive NTCP model. LASSO was first proposed by Tibshirani in 1996, and details can be found in the reference \[[@pone.0131736.ref029]\]; it uses the following eq to diminish the coefficients and select the risk factors: $$\arg\ \min_{\beta}\,\left\| {Y - X\beta} \right\|^{2}\mspace{6mu}\text{subject\ to}\ \left\| \beta \right\| = {\sum\limits_{j = 0}^{n}\left| \beta_{j} \right|} \leq t$$ where *n* is the number of variables selected, and t represents the tuning parameters that control the degree of penalty that can be determined by cross-validation \[[@pone.0131736.ref014], [@pone.0131736.ref018]\]. The default cross-validation in SPSS was used to obtain the best risk factor subsets. The risk factors selected were used for the definite NTCP model of SRP. After selecting the risk factors with the optimal performance, odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for the selected risk factors in the model. Model performance was described using different validation tools \[[@pone.0131736.ref015], [@pone.0131736.ref018]\]. The system performance was expressed using the AUC (area under the receiver operating characteristic curve), Brier score, Nagelkerke's R^2^, χ^2^, and Hosmer-Lemeshow test \[[@pone.0131736.ref015], [@pone.0131736.ref018]\].

The most significant dose-volume predictive factor determined was considered to fit the univariate logistic NTCP model for SRP, a model with traditional techniques that can be used conveniently. The parameters for the univariate NTCP regression model were obtained. Statistical analyses were performed using SPSS version 19.0 (SPSS, Chicago, IL, USA).

Results {#sec011}
=======

In total, 93 patients were included in the analysis. After radiotherapy, 48 (52%), 29 (31%), 14 (15%) and 2 (2%) patients had lung density changes of grades 0, 1, 2 and 3, respectively, according to Arriagada's classification and CT images \[[@pone.0131736.ref025], [@pone.0131736.ref026]\]. There were 50 patients (54%), 43 (46%) and 0 (0%) patients with clinical symptomatic pneumonitis of grades 0, 1 and 2, respectively, based on the CTC-NCIC \[[@pone.0131736.ref005], [@pone.0131736.ref024]\]. Patients without SPR were classified as group 0 (n = 62) and those with SPR as group 1 (n = 31). In total, 33.3% (31/93) of the patients suffered from SPR ([Table 1](#pone.0131736.t001){ref-type="table"}). A typical breast cancer treatment plan is shown in [Fig 1(A)](#pone.0131736.g001){ref-type="fig"}, an SRP diagnosis after RT is shown in [Fig 1(B)](#pone.0131736.g001){ref-type="fig"}, and an image of diagnosed SRP fused with the original isodose curves is shown in [Fig 1(C)](#pone.0131736.g001){ref-type="fig"}. The initial dosimetric and clinical predictive factors are shown in [Table 2](#pone.0131736.t002){ref-type="table"}. The most significant dosimetric and clinical predictive factors for the logistic regression NTCP model were determined using the LASSO technique. First, factors were ranked based on how strongly they were correlated using LASSO; second, the optimal number of risk factors was chosen based on the Hosmer-Lemeshow test and the area under the receiver operating characteristic curve (AUC). The risk factors in the multivariate logistic regression analysis were ranked according to LASSO predictions in descending order as shown in [Table 3](#pone.0131736.t003){ref-type="table"}.

![(a) A sample breast cancer treatment plan, (b) diagnosed with RP at 3 months after RT, (c) diagnosed with RP image fused with the original isodose curves.\
*Abbreviation*: RP: radiation pneumonitis; RT: radiotherapy.](pone.0131736.g001){#pone.0131736.g001}

10.1371/journal.pone.0131736.t001

###### Characteristics of patients.

![](pone.0131736.t001){#pone.0131736.t001g}

                                    Group (n = 93) Value---x (%)   Group 0 (n = 62) Value---x (%)   Group 1 (n = 31) Value---x (%)
  --------------------------------- ------------------------------ -------------------------------- --------------------------------
  **Age (y)**                                                                                       
  Median/Mean                       55/54.6                        55/53.5                          55/56.7
  Range                             35--92                         35--72                           36--92
  \<51                              26 (28)                        21 (34)                          5 (16)
  51--60                            42 (45)                        26 (42)                          16 (52)
  61--70                            22 (23)                        14 (23)                          8 (26)
  \>70                              3 (4)                          1 (1)                            2 (6)
  **BMI**                                                                                           
  Mean                              24.6                           25.1                             23.7
  Range                             17.3--40.3                     17.3--40.3                       18.2--34.7
  \<21                              12 (13)                        4 (6)                            8 (26)
  21--26                            53 (57)                        38 (61)                          15 (48)
  \>26                              28 (30)                        20 (33)                          8 (26)
  **Lung (d)**                                                                                      
  Mean                              3.14                           3.09                             3.24
  **Total (d)**                                                                                     
  Mean                              6.03                           6.14                             5.81
  **Tumor site**                                                                                    
  Left                              44 (47)                        32 (52)                          12 (39)
  Right                             49 (53)                        30 (48)                          19 (61)
  **SCF**                                                                                           
  NO                                65 (70)                        48 (77)                          17 (55)
  YES                               28 (30)                        14 (23)                          14 (45)
  **IMN**                                                                                           
  NO                                79 (85)                        53 (85)                          26 (84)
  YES                               14 (15)                        9 (15)                           5 (16)
  **Energy**                                                                                        
  6 MV                              3 (3)                          1 (2)                            2 (6)
  10 MV                             13 (14)                        11 (18)                          2 (6)
  6 MV+10 MV                        77 (83)                        50 (80)                          27 (88)
  **T stage**                                                                                       
  0                                 51 (55)                        33 (53)                          18 (58)
  1                                 34 (37)                        23 (37)                          11 (35)
  2                                 8 (8)                          6 (10)                           2 (7)
  **N stage**                                                                                       
  0                                 47 (51)                        31 (50)                          16 (52)
  1                                 27 (29)                        20 (32)                          7 (23)
  2                                 19 (20)                        11 (18)                          8 (25)
  **Surgery**                                                                                       
  PM                                51 (55)                        35 (57)                          16 (52)
  MRM                               42 (45)                        27 (43)                          15 (48)
  **Chemotherapy**                                                                                  
  NO                                35 (38)                        26 (42)                          9 (29)
  YES                               58 (62)                        36 (58)                          22 (71)
  **CT measured density changes**                                                                   
  Grade 0                           48 (52)                        48                               
  Grade 1                           29 (31)                                                         29
  Grade 2                           14 (15)                                                         14
  Grade 3                           2 (2)                                                           2
  **Symptomatic pneumonitis**                                                                       
  Grade 0                           50 (54)                        50                               
  Grade 1                           43 (46)                                                         43
  Grade 2                           0                                                               0
  **SRP**                                                                                           
  Group 0                           62 (67)                        62                               
  Group 1                           31 (33)                                                         31

*Abbreviation*: Group 0: Without symptomatic radiation pneumonitis; Group 1: Symptomatic radiation pneumonitis

BMI: body mass index; SCF: Irradiation to supraclavicular fossa; IMN: Irradiation to internal mammary lymph nodes; PM: partial mastectomy; MPM: modified radical mastectomy; SRP: Symptomatic radiation pneumonitis; Lung (d): maximum Lung depth from chest wall to tangential line between extreme points of PTV in the section of nipple on CT image

Total (d): maximum depth from skin to tangential line between extreme points of PTV in the section of nipple on CT image

10.1371/journal.pone.0131736.t002

###### Candidate predictive factors initially.

![](pone.0131736.t002){#pone.0131736.t002g}

  No.   Description    Range or Classification                       Median or frequency   p-valve
  ----- -------------- --------------------------------------------- --------------------- ---------
  1     MLD            13.76--28.64                                  20.52                 0.005
  2     IV5            24.43--83.56                                  60.41                 0.014
  3     IV10           32.20--68.05                                  49.64                 0.005
  4     IV13           18.22--62.73                                  45.74                 0.003
  5     IV15           26.84--60.49                                  44.21                 0.003
  6     IV20           23.28--56.61                                  40.99                 0.001
  7     IV25           20.52--53.79                                  37.88                 0.004
  8     IV30           17.99--50.74                                  35.31                 0.008
  9     IV40           10.37--44.67                                  28.29                 0.038
  10    IV50           2.49--32.41                                   11.37                 0.188
  11    AIV5           304.64--1214.54                               711.23                0.053
  12    AIV10          288.86--977.83                                584.86                0.039
  13    AIV13          227.20--908.85                                539.45                0.022
  14    AIV15          222.91--877.27                                522.36                0.025
  15    AIV20          187.53--818.15                                483.85                0.017
  16    AIV25          167.25--772.34                                447.08                0.019
  17    AIV30          152.15--730.36                                417.27                0.033
  18    AIV40          121.43--631.27                                333.60                0.066
  19    AIV50          16.14--393.78                                 133.45                0.118
  20    Age            35--92                                        54.61                 0.132
  21    BMI            17.35--40.35                                  24.64                 0.093
  22    Lung (d)       0.81--5.23                                    3.14                  0.368
  23    Total (d)      2.98--10.13                                   6.03                  0.345
  24    Tumor site     0,1[^\#^](#t002fn003){ref-type="table-fn"}    44,49                 0.242
  25    Chemotherapy   0,1[\*](#t002fn004){ref-type="table-fn"}      35,58                 0.229
  26    Energy         0,1,2[^&^](#t002fn006){ref-type="table-fn"}   3,13,77               0.212
  27    IMN            0,1[\*](#t002fn004){ref-type="table-fn"}      79,14                 0.838
  28    SCF            0,1[\*](#t002fn004){ref-type="table-fn"}      65,28                 0.028
  29    Surgery        0,1[^ѱ^](#t002fn005){ref-type="table-fn"}     51,42                 0.659
  30    T stage        0,1,2                                         51,34,8               0.840
  31    N stage        0,1,2                                         47,27,19              0.517

*Abbreviation*: BMI: body mass index; SCF: Irradiated to supraclavicular fossa; IMN: Irradiated to internal mammary lymph nodes

MLD: mean dose to the ipsilateral lung; IV5-IV50: ipsilateral lung volume received 5-50Gy (%); p-valve: univariate logistic test; AIV5-AIV50: absolute ipsilateral lung volume received 5-50Gy (cc); p-valve: univariate logistic test

^\#^0 = Left, 1 = Right

\*0 = No, 1 = Yes

^ѱ^0 = PM (partial mastectomy), 1 = MRM (modified radical mastectomy)

^&^0 = 6MV, 1 = 10MV, 2 = 6+10MV; T stage: 0 = T0, T1 (T1a, T1b, T1c, T1m, T1s), 1 = T2, 2 = T3, T4 (T4a, T4b)

N stage: 0 = N0, 1 = N1 (N1, N1a), 2 = N2 (N2, N2a), N3 (N3, N3a, N3b)

Lung (d): maximum Lung depth from chest wall to tangential line between extreme points of PTV in the section of nipple on CT image; Total (d): maximum depth from skin to tangential line between extreme points of PTV in the section of nipple on CT image

10.1371/journal.pone.0131736.t003

###### Predictive factors correlation ranked by LASSO.

![](pone.0131736.t003){#pone.0131736.t003g}

  Predictive factors                                                                
  -------------------- -------------- ------ ------------ ------ ----------- ------ -------
  1\.                  IV20           9\.    Tumor site   17\.   AIV25       25\.   IV25
  2\.                  Energy         10\.   Lung (d)     18\.   IV13        26\.   AIV30
  3\.                  Age            11\.   IV40         19\.   AIV50       27\.   IV50
  4\.                  BMI            12\.   Surgery      20\.   MLD         28\.   IV15
  5\.                  T stage        13\.   AIV40        21\.   AIV5        29\.   AIV10
  6\.                  SCF            14\.   IV10         22\.   IV5         30\.   AIV15
  7\.                  Chemotherapy   15\.   IV30         23\.   Total (d)   31\.   IMN
  8\.                  N stage        16\.   AIV20        24\.   AIV13              

*Abbreviation*: LASSO: least absolute shrinkage and selection operator; BMI: body mass index

SCF: Irradiated to supraclavicular fossa; IMN: Irradiated to internal mammary lymph nodes; MLD: mean dose to the ipsilateral lung; IV5-IV50: ipsilateral lung volume received 5-50Gy (%); AIV5-AIV50: absolute ipsilateral lung volume received 5-50Gy (cc); Definition of risk factors: Same as [Table 2](#pone.0131736.t002){ref-type="table"}.

Lung (d): maximum Lung depth from chest wall to tangential line between extreme points of PTV in the section of nipple on CT image; Total (d): maximum depth from skin to tangential line between extreme points of PTV in the section of nipple on CT image

The optimal number of risk factors selected using LASSO with cross validation was five, which included the percentage of the ipsilateral lung volume that received more than 20 Gy (IV20), energy, age, body mass index (BMI) and T stage. All corresponding coefficients of the multivariate logistic regression NTCP models are shown in [Table 4](#pone.0131736.t004){ref-type="table"}. The NTCP value for each individual patient can be calculated using the following logistic regression formula: *NTCP* = (1 + *e* ^−*S*^)^−1^, the optimal model, where $$\begin{array}{l}
{\text{S} = \text{-}6.868 + (\text{IV}20\ *0.183) + (\text{Energy}\ *\ \text{corresponding\ value}) + (\text{Age}\ *0.045) + (\text{BMI}\ *\text{-}0.093) + (\text{T\ stage}\ *} \\
{\text{corresponding\ value}).} \\
\end{array}$$

10.1371/journal.pone.0131736.t004

###### Multivariate logistic regression coefficients and odds ratios for the NTCP model.

![](pone.0131736.t004){#pone.0131736.t004g}

  Predictive factors (n = 5)                           β        *p*     Odds Ratio   95% CI
  ---------------------------------------------------- -------- ------- ------------ --------------
  IV20                                                 0.183    0.001   1.201        1.083--1.330
  Energy[^&^](#t004fn002){ref-type="table-fn"} (6MV)            0.166                
  E(1) (10MV)                                          -2.576   0.103   0.076        0.003--1.676
  E(2) (6+10MV)                                        -1.164   0.401   0.312        0.021--4.712
  Age                                                  0.045    0.103   1.046        0.991--1.105
  BMI                                                  -0.093   0.207   0.911        0.788--1.053
  T stage (T0, T1)                                              0.207                
  T(1) (T2)                                            -0.904   0.139   0.405        0.122--1.343
  T(2) (T3, T4)                                        -1.369   0.166   0.254        0.037--1.766
  Constant                                             -6.868   0.041   0.001        

*Abbreviation*: IV20: the ipsilateral lung volumes receiving doses of 20Gy; BMI: body mass index; CI: confidence interval

^&^0 = 6MV, 1 = 10MV, 2 = 6+10MV; T stage: 0 = T0, T1 (T1a, T1b, T1c, T1m, T1s), 1 = T2, 2 = T3, T4 (T4a, T4b)

Statistical positive associations were observed among the incidence of SRP, IV20, and patient age. Energy, BMI and T stage showed a negative association with SRP incidence but without significance.

The overall performance of the NTCP model for SRP incidence in terms of the AUC, Nagelkerke R^2^, Omnibus, and Hosmer--Lemeshow test was satisfactory and corresponded well with the expected values. The AUC of the optimal model was 0.80 (95% CI 0.71--0.90). Finally, the Hosmer-Lemeshow test showed a significant correlation between predicted risk and observed outcome for the LASSO optimized model ([Table 5](#pone.0131736.t005){ref-type="table"}). The performance of the NTCP model using one to five predictors is shown in [Table 5](#pone.0131736.t005){ref-type="table"}. Comparison of the receiver operating characteristic curves of the five NTCP models for SRP were shown in [Fig 2](#pone.0131736.g002){ref-type="fig"}.

![The receiver operating characteristic curves (ROC) of the five normal tissue complication probability models for symptomatic radiation pneumonitis in breast cancer patients treated with hybrid IMRT.\
Five factors: IV20, energy, age, body mass index (BMI) and T stage.](pone.0131736.g002){#pone.0131736.g002}

10.1371/journal.pone.0131736.t005

###### System performance evaluation.

![](pone.0131736.t005){#pone.0131736.t005g}

  Number of factors   AUC (CI95%)         R^2^ Nagelkerke   Omnibus   Hosmer--Lemeshow
  ------------------- ------------------- ----------------- --------- ------------------
  1                   0.70 (0.58--0.80)   0.197             \<0.001   0.228
  2                   0.76 (0.66--0.86)   0.250             \<0.001   0.220
  3                   0.78 (0.68--0.88)   0.287             \<0.001   0.613
  4                   0.78 (0.68--0.88)   0.304             \<0.001   0.892
  5                   0.80 (0.71--0.90)   0.344             \<0.001   0.201
  6                   0.80 (0.71--0.90)   0.352             \<0.001   0.022

*Abbreviation*: AUC: Area under the receiver operating characteristic curve; HL: Hosmer--Lemeshow test; the first five predictive factors were IV20, energy, age, BMI, and T stage.

The univariate dose-response fitted curve (using IV20 and AIV20) for the incidence of SRP in breast cancer patients treated with hybrid IMRT is shown in [Fig 3A and 3B](#pone.0131736.g003){ref-type="fig"}. The parameters for the univariate NTCP regression analysis shown in [Fig 3](#pone.0131736.g003){ref-type="fig"} were calculated using the percentage and the absolute of the ipsilateral lung volume that received more than 20 Gy (IV20 and AIV20). According to the NTCP curve, we determined the tolerances of IV20 and AIV20 producing a 50% complication rate (TV~50~) to be 46.7% and 660cc in breast cancer patients treated with hybrid IMRT, respectively. The tolerances IV20 and AIV20 corresponding to a 20% incidence of complications (TV~20~) was ≈ 37% and 310cc, respectively.

![The univariate logistic normal tissue complication probability models with (a) IV20 and (b) AIV20 for symptomatic radiation pneumonitis in breast cancer patients treated with hybrid IMRT.\
*Abbreviation*: IV20: ipsilateral lung volume received \>20Gy (%); AIV20: absolute ipsilateral lung volume received \>20Gy (cc); IMRT: intensity modulated radiotherapy.](pone.0131736.g003){#pone.0131736.g003}

Discussion {#sec012}
==========

RP is the most common pulmonary complication in patients receiving breast irradiation \[[@pone.0131736.ref004], [@pone.0131736.ref005]\]. RP reflects the response to radiation, including loss of pneumocytes, increased capillary permeability, interstitial and alveolar edema, and access to inflammatory cell intra-alveolar spaces \[[@pone.0131736.ref030]\]. Changes are also observed in the radiographic features, especially on CT, which not only delineates parenchymal changes better but also demonstrates the changes restricted to the irradiated area. The most common findings are ground-glass opacities and/or airspace consolidation \[[@pone.0131736.ref031], [@pone.0131736.ref032]\]. In this study, although CT density changes were found in 45 patients (48.3%), 43 patients (46.2%) had complaints consistent with pneumonitis symptoms. Because the pneumonitis symptoms are not specific, differential diagnosis is difficult. Conversely, asymptomatic RP does not affect patients' radiation therapy schedule or QoL. SRP should be more significant during radiation therapy in breast cancer patients. Therefore, establishing an NTCP model for symptomatic RP in radiation therapy for breast cancer is more important and meaningful.

Generally, the models developed in a population treated using a specific technique cannot be generalized and extrapolated to a population treated using another technique without external validation. Beetz *et al*. showed that 3D conformal radiation therapy (3D-CRT)-based models for patient-rated xerostomia among patients treated with 3D-CRT were less valid for patients treated with IMRT, and that the 3D-CRT NTCP models could not be used for IMRT cohorts \[[@pone.0131736.ref033]\]. Therefore, validation was performed for the breast cancer patients treated with hybrid IMRT instead of using the parameters obtained from 3D-CRT. Prediction of RP in breast cancer patients can be improved by using multivariate logistic regression models with the LASSO technique. When the number of factors used was increased from one (MLD) to five (IV20, energy, age, BMI and T stage), the AUC value improved from 0.67 to 0.80. Based on the associations identified, an efficient set of predictive factors can be determined to limit the risk of SRP in breast cancer patients treated with hybrid IMRT. The predictive factors included in the models are useful to optimize current IMRT treatments with regard to SRP and to indicate which predictive factors are the most important to minimize exposure of healthy tissue.

According the results of this study, the incidence of SRP in breast cancer patients after hybrid IMRT was 33.3%. The most significant risk factors selected were IV20, energy, age, BMI and T stage. Regarding dosimetric parameters, we obtained 19 absolute and percentage of ipsilateral lung volumes for V5 Gy to V50 Gy doses at specific intervals and the mean dose to the ipsilateral lung as the model predictor. The most significant dose-volume predictive factor was determined using the LASSO technique with IV20 for the logistic regression NTCP model. When only the dosimetric parameters were ranked, the orders were sorted as IV20, IV40, AIV40, IV10, IV30, AIV20, AIV25, IV13, AIV50, MLD, AIV5, IV5, AIV13, IV25, AIV30, IV50, IV15, AIV10, and AIV15. Ramella *et al*. \[[@pone.0131736.ref007]\] showed that adding IV20 and IV30 to the classical total lung constraints reduced pulmonary toxicity in concurrent chemoradiation treatment. They suggested that not all beam entrances should be on the ipsilateral lung. A conservative approach would be to use the constraint settings IV20 and IV30 as simple predictive factors of lung injury. This is consistent with our results showing that IV20 was the greatest risk predictor for the model; as IV20 increased, the RP incidence increased. Goldman *et al*. \[[@pone.0131736.ref034]\] showed that minimizing the percentage of the ipsilateral lung dose to V20 \< 30% can significantly reduce moderate to severe radiological changes and symptomatic pneumonitis based on chest X-rays. In the current study, when the dose to the ipsilateral lung volume was limited to IV20 \< 30%, the incidence of RP was 0% in our cohort treated with hybrid IMRT. Lind *et al*. \[[@pone.0131736.ref004]\] concluded that the incidence of short-term moderate pulmonary complications in adjuvant locoregional 3D RT for breast cancer is clinically significant. Their results also suggested an association of pulmonary complications with increasing age and incidentally irradiated lung volume (IV20). These results are in agreement with our analysis for the patients treated with hybrid IMRT. This is one advantage of transitioning into the era of hybrid IMRT and potentially more unconstrained beam arrangements \[[@pone.0131736.ref008]\].

In this study, a significant correlation between IV20 and MLD was found. The covariate MLD did not significantly influence the outcome based on multivariate analysis. The mean dose administered to the ipsilateral lung did not show significance in the group with grade 1+ RP toxicity. The MLDs were 21.76 Gy and 19.89 Gy for the groups with and without RP toxicity, respectively. Conversely, IV20 was the most significant dosimetric predictor for the model; therefore, a single IV20 univariate NTCP regression model was considered for convenience use. To our knowledge, no univariate NTCP model IV20 exists. In the univariate NTCP analysis, the TV~50~ for IV20 volume (50% cutoff point) was 46.7% in breast cancer patients treated with hybrid IMRT. We suggest that to maintain the incidence of grade SRP below 20%, the percentage IV20 volume should be limited to \< 37%. For AIV20, TV~50~ for AIV20 volume was 660cc and TV~20~ for AIV20 volume was 310cc, respectively.

The constrains of lungs could be intervened and controlled well in a careful radiation therapy treatment planning. However, there are still innate patients' characteristics for the risk of SPR. Once the dosimetric issue was controlled, patient age (≥ 55 years, median age) was associated with the risk of pulmonary complications. Our results are consistent with other studies on breast cancer patients \[[@pone.0131736.ref035]--[@pone.0131736.ref038]\]. Kahán *et al*. indicated that the risks of early and late radiogenic lung sequelae after 3D conformal radiotherapy in breast cancer patients were strongly associated with patient age, volume of the irradiated lung, and the applied dose \[[@pone.0131736.ref035]\]. Their results show that increased attention is necessary when radiotherapy is administered to patients over 59 years of age. Age is one of the most significant predictors of lung sequelae in patients treated using hybrid IMRT. Increasing age has been correlated with both clinical symptoms and radiological changes \[[@pone.0131736.ref004], [@pone.0131736.ref026]\].

Furthermore, BMI showed a negative, but not significant, association with the incidence of RP in patients treated with hybrid IMRT. Abe *et al*. \[[@pone.0131736.ref039]\] reported similar results; the BMIs of symptomatic patients were significantly lower than those of asymptomatic patients (*p* = 0.014). Hernando *et al*. \[[@pone.0131736.ref006]\] illustrated that relative weight loss during the 6-month period before RT referral was associated with fewer cases of RP, which contradicts our results. Allen *et al*. \[[@pone.0131736.ref040]\] retrospectively analyzed the records of 200 node-positive breast cancer patients treated with 3D-CRT. Of the 14 patients with RP, 9 (64%) had a BMI \> 27, compared with 9 out of the 42 (21%) patients in the control group (*p* = 0.0065). Although BMI was correlated highly with RP, pulmonary comorbidities and IV20 were also relevant. Physicians should consider these risk factors when treating patients. However, treatment methods may differ among nations and institutions. Differences in area and radiation modality may produce different types and levels of RP toxicity. Energy and T stage showed a non-significant negative association with the incidence of RP in patients treated with hybrid IMRT. Using higher energy photons not only improve skin sparing effect but also can obtain better target dose uniformity and lacking lateral scattering in the low-density lung \[[@pone.0131736.ref041]\], making SRP less than the lower energy modality had. The treatment target after surgical intervention may be the cause of negative association between the T-stage and the incidence of SRP. Early stage breast cancer performed partial mastectomy (PM) mostly, whereas modified radical mastectomy (MRM) for advanced stage. The target after PM includes the whole beast and boost, which implies a higher and ununiformed dose distribution. The target after MRM is the chest wall with /without axilla. The shape of the target is smoother and easily to achieve a satisfied requirement in treatment planning. No matter how, there is no statistic significant in Energy and T stage.

Post-chemotherapy status, a non-dosimetric factor that may affect the risk of SRP in patients, is an issue that needs to be addressed. Our report showed no association between SRP and chemotherapy, which is in agreement with other reported data \[[@pone.0131736.ref042], [@pone.0131736.ref043]\]. Lind *et al*. \[[@pone.0131736.ref043]\] showed that pulmonary complications and concurrent tamoxifen intake or pre-RT adjuvant chemotherapy were not correlated. However, other treatment series have reported associations between chemotherapy and RT \[[@pone.0131736.ref025], [@pone.0131736.ref044]\].

In this study, the irradiation of internal mammary nodes (IMNs) was not statistically significant in the multivariate model. To irradiate IMNs, the irradiated field extends to the sternum-costal space, which may increase the radiation exposure to the lung. However, IMN irradiation was ranked thirty-first and did not significantly influence the outcome based on multivariate analysis. Hooning *et al*. \[[@pone.0131736.ref045]\] showed in cases of IMN irradiation, via a direct anterior field, that the heart and coronary arteries are exposed to similar doses in the left- and right-side fields. In their study, many patients received radiation to IMNs via the anterior field, and no difference in risk between left- and right-sided tumors was found. Lind *et al*. \[[@pone.0131736.ref004]\] reported that the frequency and severity of pulmonary complications in patients treated with locoregional RT including IMNs (approximately 10% treated with corticosteroids) created a clinically significant problem, especially when RT was used as an adjuvant. In the present study, the univariate analysis for IMNs showed no significance (*p* = 0.92). Similarly, the factors that may affect the irradiated volume of the lungs, Lung (d) and Total (d), were not significant for SRP in this study. The definition of Lung (d) is the maximum lung depth from the chest wall to the tangential line between extreme planning target volume (PTV) points in the nipple area on CT images, and Total (d) is the maximum depth from skin to tangential line between extreme PTV points in the nipple area on CT images. The dosimetric factors still appear to be the most significant for symptomatic pneumonitis based on the results of this study.

Smoking may be a significant predictor for the risk of pulmonary complications. Theuws *et al*. \[[@pone.0131736.ref038]\] and Johansson *et al*. \[[@pone.0131736.ref046]\] found a lower incidence of RP in breast cancer patients who smoked. Kahán *et al*. \[[@pone.0131736.ref035]\] showed an association between smoking and radiation lung injury in breast cancer patients that is controversial. However, we did not take the effects of smoking into consideration because at the time of RT referral only three patients were smokers and none of these had SRP.

SRP not only reduces the QoL but also the compliance of breast cancer patients in radiation therapy. A careful radiation therapy treatment planning in breast irradiation could overmaster dosimetric issue to lung. However, innate patients' characteristics are still to be the risks for SPR. Therefore, it should pay more attention to the elderly or low-BMI breast cancer patients before and after radiation therapy in clinical practice. On the other hand, this study was limited by the small number of patients available. The predictive power could be improved by increasing the sample size. In addition, the selected NTCP parameters could be generalized and extrapolated to other breast cancer patient groups or radiation therapy for other diseases in future studies.

Conclusion {#sec013}
==========

Our analyses indicate an increased risk of SRP in elderly and low-BMI breast cancer patients once the percentage of ipsilateral lung volume that receives more than 20-Gy of hybrid IMRT is under controlled. The risk factors included in the model are useful to optimize current hybrid IMRT planning. We suggest to a dose-volume constraint of IV20 \< 37% (or AIV20 \< 310cc) for the irradiated ipsilateral lung to maintain incidence of SPR below 20%, and pay attention to the sequelae especially in elderly or low-BMI breast cancer patients.
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